Lund, L
My experience
95% CI, 1.412.75) in the CANVAS CVOT, which overall included 10,142 patients with T2DM and high cardiovascular risk [75]
However, newer medications target multiple metabolic hormones: GLP-1 drugs (single-hormone): semaglutide medications like Wegovy and Ozempic Dual-agonist drugs: tirzepatide medications like Mounjaro and Zepbound (target GLP-1 and GIP receptors) Triple-agonist drugs: retatrutide (targets GLP-1, GIP and glucagon receptors) Researchers believe stimulating multiple hormone pathways may produce stronger effects on appetite, metabolism and energy expenditure
Key risks include: Increased risk of cancer coming back Chemotherapy not working as well Possible nerve problems When Combined Therapy Might Be Appropriate In some cases, Vitamin B12 and folic acid together might be good with a doctors watch
In the wildtype cell line, GLP-1, oxyntomodulin and exendin-4 competition curves were clearly biphasic, with potencies for the high affinity site correlating with those reported from whole cell binding assays in the wildtype GLP-1R expressing ChoFlpIn cell line used in the mutagenesis study (Figure 7A, Supplemental Figures 5-6)
